IGI Logo

Alembic Pharmaceuticals is currently trading at Rs. 602.05, up by 23.60 points or 4.08% from its previous closing of Rs. 549.95 on the BSE.

The scrip opened at Rs. 580.35 and has touched a high and low of Rs. 602.00 and Rs. 574.90 respectively. So far 14552 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 847.95 on 04-Jan-2022 and a 52 week low of Rs. 541.10 on 20-Oct-2022.

Last one week high and low of the scrip stood at Rs. 604.00 and Rs. 542.50 respectively. The current market cap of the company is Rs. 11811.48 crore.

The promoters holding in the company stood at 69.61%, while Institutions and Non-Institutions held 17.87% and 12.52% respectively.

Alembic Pharmaceuticals has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Mesalamine Extended-Release Capsules USP, 0.375 g. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Apriso Extended-Release Capsules, 0.375 g, of Salix Pharmaceuticals, Inc. (Salix). Mesalamine Extended-Release Capsules are indicated for the maintenance of remission of ulcerative colitis in adults.

Mesalamine Extended-Release Capsules USP, 0.375 g, have an estimated market size of $133 million for twelve months ending June 2022 according to IQVIA. The company has a cumulative total of 174 ANDA approvals (150 final approvals and 24 tentative approvals) from USFDA.

Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907.